Cargando…

Acceptability of cannabidiol in patients with psychosis

BACKGROUND: Cannabidiol (CBD) is a promising novel candidate treatment for psychosis. It has a more benign side effect profile than antipsychotic medications, and being treated with CBD is not perceived as being stigmatising. These observations suggest that patients with psychosis would find CBD to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chesney, Edward, Lamper, Doga, Lloyd, Millie, Oliver, Dominic, Hird, Emily, McGuire, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608242/ https://www.ncbi.nlm.nih.gov/pubmed/36312845 http://dx.doi.org/10.1177/20451253221128445

Ejemplares similares

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
por: Chesney, Edward, et al.
Publicado: (2020)

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
por: Chesney, Edward, et al.
Publicado: (2020)

The Placebo Effect in Psychosis: Why It Matters and How to Measure It
por: Hird, Emily J., et al.
Publicado: (2023)

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study
por: Oliver, Dominic, et al.
Publicado: (2020)

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
por: Appiah-Kusi, E., et al.
Publicado: (2020)

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
por: Englund, Amir, et al.
Publicado: (2022)

Prevalence of Neuroradiological Abnormalities in First-Episode Psychosis: A Systematic Review and Meta-analysis
por: Blackman, Graham, et al.
Publicado: (2023)

M136. PSYCHOSIS POLYRISK SCORE (PPS): IMPROVING DETECTION OF INDIVIDUALS AT-RISK AND PREDICTION OF CLINICAL OUTCOMES
por: Oliver, Dominic, et al.
Publicado: (2020)

M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS
por: Hird, Emily, et al.
Publicado: (2020)

How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis?
por: Kempton, Matthew J., et al.
Publicado: (2015)

F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?
por: Oliver, Dominic, et al.
Publicado: (2018)

Cannabidiol modulation of hippocampal glutamate in early psychosis
por: O’Neill, Aisling, et al.
Publicado: (2021)

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
por: Davies, Cathy, et al.
Publicado: (2020)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA
por: McGuire, Philip, et al.
Publicado: (2018)

Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis
por: Davies, Cathy, et al.
Publicado: (2018)

Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
por: Allen, Paul, et al.
Publicado: (2021)

Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies
por: Oliver, Dominic, et al.
Publicado: (2018)

Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis
por: Merritt, Kate, et al.
Publicado: (2013)

Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
por: Allen, Paul, et al.
Publicado: (2021)

T97. REAL WORLD IMPLEMENTATION OF A TRANSDIAGNOSTIC RISK CALCULATOR FOR THE AUTOMATIC DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN CLINICAL ROUTINE
por: Oliver, Dominic, et al.
Publicado: (2020)

Real World Implementation of a Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk of Psychosis in Clinical Routine: Study Protocol
por: Fusar-Poli, Paolo, et al.
Publicado: (2019)

A qualitative study of the acceptability of cognitive bias modification for paranoia (CBM-pa) in patients with psychosis
por: Leung, C. J., et al.
Publicado: (2019)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

Neural and Behavioral Correlates of Aberrant Salience in Individuals at Risk for Psychosis
por: Roiser, Jonathan P., et al.
Publicado: (2013)

17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.
por: Ranganathan, Mohini, et al.
Publicado: (2018)

Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust
por: Fusar-Poli, Paolo, et al.
Publicado: (2019)

Speech Illusions in People at Clinical High Risk for Psychosis Linked to Clinical Outcome
por: Hird, Emily J, et al.
Publicado: (2022)

What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors
por: Oliver, Dominic, et al.
Publicado: (2020)

Hippocampal circuit dysfunction in psychosis
por: Knight, Samuel, et al.
Publicado: (2022)

Meta-analysis of longitudinal neurocognitive performance in people at clinical high-risk for psychosis
por: Hedges, Emily P., et al.
Publicado: (2022)

Psychiatric and neuropsychiatric syndromes and COVID-19 – Authors' reply
por: Rogers, Jonathan P, et al.
Publicado: (2020)

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic
por: Rogers, Jonathan P, et al.
Publicado: (2020)

Correction: Hippocampal circuit dysfunction in psychosis
por: Knight, Samuel, et al.
Publicado: (2022)

Real-world implementation of precision psychiatry: Transdiagnostic risk calculator for the automatic detection of individuals at-risk of psychosis
por: Oliver, Dominic, et al.
Publicado: (2021)

Cariprazine as a treatment for negative psychotic symptoms in first-episode psychosis: case series
por: Demjaha, Arsime, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_34ov0u375m950vl982aspmr05q